Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Trifecta-Kidney cfDNA-MMDx Study
NCT04239703 · View on ClinicalTrials.gov ↗
Study Summary
Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood, and the Molecular Microscope® (MMDx) Diagnostic System results in indication biopsies.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Prospera
- DIAGNOSTIC_TEST HLA antibody
- DIAGNOSTIC_TEST MMDx
Study Locations (20)
Other
- Department of Nephrology, The Royal Melbourne Hospital 1 South East — Melbourne
- University Hospital Merkur Renal Division — Zagreb
- Institute for Clinical and Experimental Medicine (IKEM) — Prague
- Charite-Medical University of Berlin Department of Nephrology — Berlin
- Centre of Nephrology, Vilnius University Hospital Santaros Klinikos — Vilnius
- Department of Nephrology and Transplantation Medical University in Bialystok — Bialystok
- University Hospital nr1 Bydgoszcz, Klinika Transplantologii — Bydgoszcz
Maryland
- University of Maryland School of Medicine — Baltimore
- The Johns Hopkins University, School of Medicine — Baltimore
Michigan
- Detroit Medical Center, Harper University Hospital of Wayne State University — Detroit
- Henry Ford Hospital — Detroit
Ohio
- University Hospitals Cleveland Medical Ctr. — Cleveland
- Cleveland Clinic — Cleveland
Florida
- Tampa General Hospital — Tampa
Missouri
- Barnes-Jewish Hospital, Washington University at St. Louis — St Louis
Utah
- Intermountain Transplant Services — Murray
Virginia
- Virginia Commonwealth University Medical Center — Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2019-12-01 |
| Est. Completion | 2027-12 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04239703
The ClinicalTrials.gov registry entry for NCT04239703 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alberta, which has 135 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Kidney Transplant Rejection appearing as the primary indexed condition, and to 3 interventions — of which Prospera is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04239703 reports 20 study locations spanning 11 distinct geographic areas — top geographies include Other, Maryland, Michigan. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04239703 about?
NCT04239703 is a clinical study titled "Trifecta-Kidney cfDNA-MMDx Study". Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood, and the Molecular Microscope® (MMDx) Diagnostic System results in indication biopsies.
What is the current status of trial NCT04239703?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2019-12-01. Estimated completion is 2027-12.
What conditions does trial NCT04239703 study?
This clinical trial studies the following conditions: Kidney Transplant Rejection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04239703?
The interventions under investigation include: Prospera (DIAGNOSTIC_TEST), HLA antibody (DIAGNOSTIC_TEST), MMDx (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04239703?
This trial is sponsored by University of Alberta, which has 135 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04239703 being conducted?
This trial has 20 study locations across Florida, Maryland, Michigan, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.